Copyright
©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 21, 2017; 23(31): 5823-5828
Published online Aug 21, 2017. doi: 10.3748/wjg.v23.i31.5823
Published online Aug 21, 2017. doi: 10.3748/wjg.v23.i31.5823
Tegafur-uracil-induced rapid development of advanced hepatic fibrosis
Shuya Honda, Koji Sawada, Takumu Hasebe, Shunsuke Nakajima, Mikihiro Fujiya, Toshikatsu Okumura, Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan
Author contributions: Honda S, Sawada K, Hasebe T and Nakajima S treated this patient; Sawada K, Fujiya M and Okumura T wrote the paper.
Institutional review board statement: This study was approved by the Institutional Review Board of Asahikawa Medical University.
Informed consent statement: Written informed consent was obtained prior to this manuscript preparation.
Conflict-of-interest statement: All the authors have no conflicts of interests to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Koji Sawada, MD, PhD, Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido 078-8510, Japan. k-sawada@asahikawa-med.ac.jp
Telephone: +81-166-682462 Fax: +81-166-682469
Received: February 21, 2017
Peer-review started: February 22, 2017
First decision: June 5, 2017
Revised: June 22, 2017
Accepted: July 22, 2017
Article in press: July 24, 2017
Published online: August 21, 2017
Processing time: 178 Days and 21.8 Hours
Peer-review started: February 22, 2017
First decision: June 5, 2017
Revised: June 22, 2017
Accepted: July 22, 2017
Article in press: July 24, 2017
Published online: August 21, 2017
Processing time: 178 Days and 21.8 Hours
Core Tip
Core tip: This case report presents a rapid development of hepatic fibrosis induced by tegafur-uracil and the usefulness of a non-invasive assessment of hepatic fibrosis. Tegafur-uracil is often administered in patients with various cancers; therefore, when liver dysfunction progresses in patients treated with tegafur-uracil, the development of hepatic fibrosis should be considered, even for short-term administration.